Please login to the form below

Not currently logged in
Email:
Password:

EU patent extension for Pfizer's Lipitor

The European patent for Pfizer's blockbuster cholesterol drug, Lipitor, could be extended by six months due to new paediatric data concerning the treatment

The European patent for Pfizer's blockbuster cholesterol drug, Lipitor (atorvastatin), could be extended by six months due to new paediatric data concerning the treatment.

According to the Financial Times, the extended exclusivity to May 2012 for what is currently the company's largest selling therapy could earn Pfizer $800m.

Pfizer has said it plans to launch a chewable grape-flavoured version of Lipitor for children in the EU by November 2011.

The launch would coincide with the expiration of Lipitor's patent, when the opening of the market to generic competition would be expected to have a dramatic effect on the drug's current £11bn annual revenue.

However, Pfizer has requested a supplementary protection certificate across the EU, which would extend the company's control over supplies and pricing of Lipitor a further six months.

The certificate is part of EU regulations designed to encourage paediatric research regarding medicines.

Lipitor is usually prescribed to adults with high levels of cholesterol, however it can be given to children with the condition familial hypercholesterolaemia - a specific type of inherited high cholesterol that runs in the family.

11th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics